Passage Bio Inc is a biotechnology company focused on developing gene therapies for targeted genetic disorders
The company leverages its expertise in genetic medicine to create innovative treatments that address the root causes of diseases, with a particular emphasis on neurological conditions. By utilizing advanced vector technology and proprietary delivery systems, Passage Bio aims to provide transformative solutions that can improve patient outcomes and enhance the quality of life for individuals affected by these challenging health issues. The organization is committed to advancing its product pipeline through rigorous research and clinical development, seeking to bring groundbreaking therapies to market.
Passage Bio Inc (NASDAQPASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for frontotemporal dementia (FTD) with
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
The Dow Jones closed higher by over 200 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
